Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

... pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

source http://www.oleantimesherald.com/business/kala-pharmaceuticals-reports-inducement-grant-under-nasdaq-listing-rule-c/article_d518985d-dd76-5c04-8510-9af09a277889.html